Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Geoffrey R. Oxnard(Foundation Medicine (United States)), Scott J. Rodig(Brigham and Women's Hospital), Gordon J. Freeman(Dana-Farber Cancer Institute), Xiaoyun Liao(Dana-Farber Cancer Institute), F. Stephen Hodi(Harvard University), Lynette M. Sholl(Brigham and Women's Hospital), David M. Jackman(Brigham and Women's Hospital), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Christine Lydon(Dana-Farber Cancer Institute), Mohit Butaney(Brigham and Women's Hospital)
Cited by 290
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k